Sumatriptan (as succinate) 3mg/0.5mL; soln for SC inj. Sumatriptan binds with high affinity to human cloned 5-HT 1B/1D receptors. Sumatriptan presumably exerts its therapeutic effects in the treatment ...
Upsher-Smith has added Zembrace SymTouch (sumatriptan) injection 3 mg to its Access Pathways Platinum Pass Program, a savings and support program where eligible patients pay $0 per prescription.
CHATHAM, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of ...
Promius Pharma announced that Zembrace SymTouch, indicated to treat acute migraine headaches with or without aura in adults, is now commercially available in the U.S. Zembrace SymTouch contains 3mg of ...
CHATHAM, N.J., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a ...
Chatham-based Tonix Pharmaceuticals Holding Corp. and its wholly owned subsidiary Tonix Medicines Inc. announced June 26 that they entered into an agreement to acquire two fast-acting migraine ...
PRINCETON, N.J., Nov. 15, 2017 /PRNewswire/ -- Promius Pharma LLC announced today that ZEMBRACE ® SymTouch ® (sumatriptan injection) 3 mg, an acute migraine headache treatment on the market since ...
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announces that it has entered into a definitive asset purchase agreement ...
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) shares are trading higher Friday after the company announced the United States Patent and Trademark Office granted a patent covering the subcutaneous ...
CHATHAM, N.J., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a ...
The Company expects that its cash resources at December 31, 2024, and the gross proceeds of approximately $30.4 million raised from sales under its at-the-market facility in the first quarter of 2025, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results